To explore the effects of estrogen replacement therapy (ERT) and recombinant growth hormone (GH) treatment on bone mineral density (BMD) in Turner’s syndrome, we assessed volumetric BMD (vBMD), which is less dependent on body and bone sizes, in these patients at final height. The areal BMD (aBMD) was measured in 26 young women with Turner’s syndrome (age range 17.5–25.0 years) by dual-energy X-ray absorptiometry, and vBMD was calculated. Patients were subdivided as group 1 (n = 12; ERT alone) and group 2 (n = 14; GH + ERT). Years of estrogen exposure were not different between the groups (group 1: 6.4 ± 1.5 years; group 2: 5.3 ± 1.7 years); in group 2, GH therapy was 5.3 ± 1.4 years. Final heights were significantly higher in group 2 than in group 1 (148.1 ± 3.0 vs. 142.0 ± 2.8 cm; p < 0.0001) as well as aBMD (1.073 ± 0.118 vs. 0.968 ± 0.122 g/cm2; p < 0.04). vBMD was higher in group 2 but not significantly different from group 1 (0.374 ± 0.030 vs. 0.358 ± 0.027 g/cm3; p = 0.169). aBMD was reduced with respect to the normative values in both groups (group 1: –1.97 ± 1.04 SDS, p < 0.0001 vs. 0; group 2: –0.93 ± 1.01 SDS, p < 0.005 vs. 0), whereas vBMD was not (group 1: –0.07 ± 0.79 SDS; group 2: 0.42 ± 0.82 SDS). Our data suggest that: in Turner’s syndrome GH administration improves final height and aBMD, but it does not significantly increase vBMD; aBMD reduction in Turner’s syndrome is likely due to the impaired growth and reduced bone size; Turner’s patients on ERT from adolescence show vBMD values in the normal range in young adulthood.

1.
Bachrach LK: Osteopenia in Turner girls; in Albertsson-Wikland K, Ranke M (eds): Turner Syndrome in a Life-Span Perspective. Amsterdam, Elsevier, 1995, pp 233–248.
2.
Saggese G, Cinquanta L, Bertelloni S: Effet du traitement hormonal sur la minéralisation osseuse dans le syndrome de Turner. Arch Pédiatr 1998;5(suppl 4):371–374.
3.
Rubin K: Turner syndrome and osteoporosis: Mechanisms and prognosis. Pediatrics 1998;102(suppl):481–485.
4.
Davies MC, Gulekli B, Jacobs HS: Osteoporosis in Turner’s syndrome and other forms of primary amenorrhoea. Clin Endocrinol (Oxf) 1995;43:741–746.
5.
Mora S, Weber G, Guarneri MP, Nizzoli G, Pasolini D, Chiumello G: Effect of estrogen replacement therapy on bone mineral content in girls with Turner syndrome. Obstet Gynecol 1992;79:747–751.
6.
Westerman F, Mokov E, Scheidhauer K, Haverkamp F, Michalk D, Schonau E: Bone status in adults with Turner syndrome (abstract). Acta Paediatr Suppl 1997;423:137.
7.
Neely EK, Marcus R, Rosenfeld RG, Bachrach LK: Turner syndrome adolescents receiving growth hormone are not osteopenic. J Clin Endocrinol Metab 1993;76:861–866.
8.
Prentice A, Parsons TJ, Cole TJ: Uncritical use of bone mineral density in absorptiometry may lead to size-related artifacts in the identification of bone mineral determinants. Am J Clin Nutr 1994;60:837–842.
9.
Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G: Measurement of volumetric bone mineral density accurately determines degree of lumbar undermineralization in children with growth hormone deficiency. J Clin Endocrinol Metab 1998;83:3150–3154.
10.
Seeman E: Growth in bone mass and size – are racial and gender differences in bone mineral density more apparent than real? J Clin Endocrinol Metab 1998;83:1414–1418.
11.
Shaw NJ, Rehant VK, Husain S, Maeshall T, Smith CS: Bone mineral density in Turner’s syndrome – a longitudinal study. Clin Endocrinol (Oxf) 1997;47:367–370.
12.
Tanner JM, Whitehouse RH, Takaishi M: Standards from birth to maturity for height, weight, height velocity: British children. Arch Dis Child 1966;41:613–635.
13.
Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and the Wrist, ed 2. Stanford, Stanford University Press, 1959.
14.
Kroger H, Kotaniemi A, Vaino P, Alhava E: Bone densitometry of the spine and femur in children by dual-energy X-ray absorptiometry. Bone Miner 1992;17:75–85.
15.
Del Rio L, Carrascosa A, Pons F, Gusinye M, Yeste D, Domenech FM: Bone mineral density of the lumbar spine in white Mediterranean Spanish children and adolescents: Changes related to age, sex, and puberty. Pediatr Res 1994;35:362–366.
16.
Stepan JJ, Musilova J, Pacovsky V: Bone demineralization, biochemical indices of bone remodeling and estrogen replacement therapy in adults with Turner syndrome. J Bone Miner Res. 1989;4:193–198.
17.
Sylvén L, Hagenfield K, Ringertz H: Bone mineral density in middle-aged women with Turner syndrome. Eur J Endocrinol 1995;132:47–52.
18.
Bertelloni S, Baroncelli GI, Ferdeghini M, Perri G, Saggese G: Normal volumetric bone mineral density in young men with histories of constitutional delay of puberty. J Clin Endocrinol Metab 1998;83:4280–4283.
19.
Ross JL, Meyrson Long L, Feuillan P, Cassorla F, Cutler GB Jr: Normal bone density of the wrist and the spine and increased wrist fractures in girls with Turner syndrome. J Clin Endocrinol Metab 1991;73:355–359.
20.
Lanes R, Gunczler P, Paoli M, Weisenger JR: Bone mineral density of prepubertal age girls with Turner’s syndrome while on growth hormone therapy. Horm Res 1995;44:168–171.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.